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Table . Comparison of patients undergoing 2nd RB according to devel-
opment of renal failure
 Renal failure (n=26) No renal failure 
(n=69)*
p
Total FU (years), mean (SD) 21 (10.4) 16.5 (9.39) 0.002
SCr (mg/dl) at 2° RB, mean (SD) 1.7 (1) 0.98 (0.35) 0.001
Proteinuria (g/24h) at 2° RB, mean (SD) 4.7 (3.9) 2.99 (2.63) 0.022
Class IV and IV+V at 2° RB, % 76.9 54.5 0.07
Hypertension at onset, % 84.6 32.4 <0.001
HCQ intake at 2° RB, % 9.5 52 <0.001
Glucocorticoids at 2° RB % 84 87 ns
Immunosuppressants at 2° RB % 40 58 ns
AI at onset, mean (SD) 7.14 (3.95) 7.02 (3.86) ns
AI at 2° RB, mean (SD) 5.37 (4.12) 4.02 (3.71) ns
CI at onset, mean (SD) 2.05 (1.88) 1.56 (1.64) ns
CI at 2° RB, mean (SD) 3.87 (3.08) 3.52 (2.16) ns
Years between 2° RB and end of FU, mean (SD)14.1 (10.5) 9.3 (8.84) ns
*Group 1 excluded
RB, renal biopsy; AI, activity index; CI, chronicity index; SCr serum creatinine; FU, follow-up; 
SD, standard deviation.
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Background: Systemic lupus erythematosus (SLE) is a systemic autoimmune/
inflammatory disease. Approximately 30% of SLE patients develop lupus nephri-
tis (LN) that affects treatment and prognosis. Easily accessible biomarkers do 
not exist to reliably predict renal disease1. Recently, calcium-binding S100 pro-
teins have been suggested as biomarkers in systemic inflammatory conditions, 
including SLE2,3.
Objectives: The MASTERPLANS Consortium aims to identify indicators of treat-
ment responses in SLE. This study tested the applicability of S100 proteins in 
serum and urine as biomarkers for disease activity and response to treatment 
with rituximab in LN.
Methods: S100A8/A9 and S100A12 proteins were quantified in the serum 
and urine of 243 SLE patients from the BILAG-BR study and 48 matched 
controls using MSD technology to determine whether they perform as bio-
markers for active LN (n=85 SLE patients) and/or may be used to predict 
response to treatment with rituximab. Renal disease activity and response 
to treatment was based on BILAG-BR scores and changes in response to 
treatment4,5.
Results: Serum S100A12 (p<0.001), and serum and urine S100A8/A9 (p<0.001) 
are elevated in SLE patients. While serum and urine S100 levels do not correlate 
with global SLE disease activity (SLEDAI), levels in urine and urine/serum ratios 
are elevated in SLE patients with active LN (S100A8/A9: urine p>0.005, urine/
serum p<0.05; S100A12: urine p<0.05, serum/urine p<0.005). S100 proteins per-
form better as biomarkers for active LN involvement in SLE patients positive for 
anti-dsDNA antibodies. Lastly, binary logistic regression and AUC analysis sug-
gests the combination of serum S100A8/A9 and S100A12 to predict response to 
RTX treatment in LN after 6 months.
Conclusion: Findings from this study show promise for clinical application of 
S100 proteins to predict active renal disease in SLE and response to treatment 
with rituximab. Significantly overlapping values between groups currently prohibit 
the definition of cut-off values and prospective studies are required to validate 
findings.
References: 
[1] Reppe Moe SE, et al. Assessing the relative impact of lupus nephritis on 
mortality in a population-based systemic lupus erythematosus cohort. 
Lupus. 2019;28(7):818-825.
[2] Austermann J, et al. S100 proteins in rheumatic diseases. Nat Rev Rheuma-
tol. 2018;14(9):528-541.
[3] Tydén H, et al. Pro-inflammatory S100 proteins are associated with glomer-
ulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus. 
Lupus. 2017;26(2):139-149.
[4] Yee CS, et al. Numerical scoring for the BILAG-2004 index. Rheumatology. 
2010; 49(9):1665-1669.
[5] McCarthy et al. Short-term efficacy and safety of rituximab therapy in refrac-
tory systemic lupus erythematosus: Results from the british isles lupus 
assessment group biologics register. Rheumatol. 2018;57(3):470-479.
Acknowledgments: Clinical information and serum/urine samples from SLE 
patients were provided by BILAG-BR centres.
Disclosure of Interests: Jennifer Davies: None declared, Angela Midgley: None 
declared, Sean Donohue: None declared, Ian N. Bruce Grant/research support 
from: Genzyme Sanofi, GSK, and UCB, Consultant of: Eli Lilly, AstraZeneca, 
UCB, Iltoo, and Merck Serono, Speakers bureau: UCB, Michael Beresford: None 
declared, Christian Hedrich Grant/research support from: Research grant sup-
port from Novartis (Molecular pathophysiology of psoriasis)., Speakers bureau: 
Speaker honoraria from Roche (pathophysiology of polyarticular JIA and sys-
temic JIA); involved in advisory boards for Novartis (systemic JIA and IL-1 medi-
ated diseases).
DOI: 10.1136/annrheumdis-2020-eular.1180
THU0251 IMMUNOPHENOTYPIC CLUSTERS OF SLE PATIENTS 
REVEAL SUBGROUPS WITH SEVERE DISEASE 
RESISTANT TO CONVENTIONAL THERAPY
A. Psarras1, D. Li2, A. Alase1, Z. Wigston1, I. Bruce3, N. Mchugh2, E. Vital1. 
1University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal 
Medicine, Leeds, United Kingdom; 2University of Bath, Bath, United Kingdom; 
3University of Manchester, Manchester, United Kingdom
Background: Biomarkers to predict response to rituximab include plasmablasts 
and, in the current MASTERPLANS consortium, Sm/U1RNP antibodies and high 
expression of IFN Score B (a subset of interferon-stimulated genes that predict 
more clinical outcomes than a classic interferon signature). The relationships 
amongst these biomarkers and their association with response to conventional 
therapies are less well described.
Objectives: To analyse the inter-relationships amongst immune biomarkers in 
two independent SLE cohorts in association with disease activity and stage of 
therapeutic pathway.
Methods: CONVAS is a cohort of unselected SLE patients; data available 
include current and historic disease activity, use of biologic therapy, flow cytom-
etry, gene expression (IFN Score A and IFN Score B), and immunoprecipitation 
for autoantibodies (n=91). BILAG-BR is a British registry study for SLE patients 
commencing biologics; data available include current and historic disease activ-
ity, gene expression (IFN Score A and IFN Score B) and immunoprecipitation 
for autoantibodies (n=112). In both cohorts, biologics were only prescribed to 
patients with active disease (BILAG 1 x A or 2 x B) and failure of either cyclo-
phosphamide or mycophenolate. Given the mixture of continuous and categori-
cal variables, data were clustered using Gower distance and Partitioning Around 
Medioids. K was chosen using silhouette coefficient and clusters visualised with 
t-Distributed Stochastic Neighbor Embedding (t-SNE).
Results: There were 6 clusters. In rituximab-naïve patients:
1.  Sm/U1RNP+, Ro60-, highest IFN Score A, low CD4+ T cells, low NK cells, 
high plasmablasts
2.  Sm/U1RNP-, Ro60+, medium IFN Score A, low CD4+ T cells, high NK cells, 
high plasmablasts
3.  Sm/U1RNP-, Ro60-, lowest IFN Score A, high CD4+ T cells, low NK cells, low 
plasmablasts
Other antibody subtypes and flow cytometric markers did not improve the accu-
racy of clustering. In rituximab-treated patients, 3 equivalent clusters for antibody 
subtypes and IFN Score A were observed but differentiated due to flow cytometry 
findings, as expected after rituximab treatment. Overall, the patients in the clus-
ter defined by Sm/U1RNP antibodies and high IFN Score A were notable for a 
higher rate of prior disease activity in the renal, neurological and general BILAG 
domains (Table 1).
Table 1 : Clinical features in unselected SLE patients (CONVAS)
System affected (ever) Sm/U1RNP & high IFN 
Score A (n=27)
Other
(n=92)
p value
General 14/27 (52%) 24/92 (26%) 0.02
Mucocutaneous 23/27 (85%) 73/92 (79%) 0.50
Neuro 10/27 (37%) 17/92 (19%) 0.04
MSK 25/27 (93%) 83/92 (90%) 0.71
Cardiorespiratory 9/27 (33%) 20/92 (22%) 0.22
Renal 12/27 (44%) 15/92 (16%) 0.005
Haematology 25/27 (93%) 67/92 (73%) 0.03
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